Fig. 4
From: Optimization of the antimicrobial peptide Bac7 by deep mutational scanning
Characterization of Bac7PS and Bac71-23. a MICs of a panel of clinical isolates of E. coli (n=45) including MDR bacteria (ESBL, CRE, n = 25). MIC50 of Bac71-23 = 7.5 μM, MIC50 of Bac7PS = 2.9 μM. b Membrane damage assays measuring GFP loss (% of cells that lost GFP fluorescence) and PI uptake (% cells that gained PI fluorescence) when incubating E. coli TOP10 in MHB II for 30 min in the presence of increasing concentrations of Bac7PS and Bac71-23 (n = 3; error bars = 1SD). MIC of melittin against E. coli TOP10 is 5.0 μM (data not shown). c In vitro translation inhibition assays against E. coli ATCC 29522 (left) and HEK 293 ribosomes (right). IC50 values are extracted from a luminescence assay translating firefly luciferase mRNA peptide concentrations between 800 and 0.08 μM (n = 9). p-values (p) are calculated by performing a Wilcoxon rank-sum test, testing for differences in mean IC50 values of Bac71-23 and Bac7PS